Cravacin (Deucravacitinib) is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Clinical Trial Results of Cravacin (Deucravacitinib)

(A generic Version of SOTYKTU)

Clearer Skin at 16 Weeks:

In one study, most people taking Deucravacitinib experienced a 75% improvement in skin clarity by Week 16, compared to 9% of those on a placebo (53% vs. 9%).
The study also assessed skin clearance using another method, finding that about 50% of participants on Deucravacitinib achieved clear or nearly clear skin by Week 16, while only 9% of those on placebo saw the same results.
Additionally, 16% of people treated with Deucravacitinib had completely clear skin at Week 16, compared to just 1% of those receiving a placebo.
Individual results may vary.